Induced Proximity and Targeted Protein Degradation: Emerging Technologies and Therapeutic Applications (S1)
January 1-4, 2027
| Location to be Determined
Christina Woo, William Forrester and Alessio Ciulli
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Saturday, January 2, 2027
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Craig M. Crews †, Yale University
Regulated Induced Proximity Targeting Chimeras—RIPTACs—A Heterobifunctional Small Molecule Strategy for Cancer Selective Therapies: Cell Chemical Biology |
|
| 9:00–11:15 AM |
Clinic to First Approval, TPD Medicinal Chemistry to in vivo |
|
| |
Angela Cacace †, Arvinas Inc
Neurodegenerative Targets in TPD |
|
| |
Juliet Williams †, Kymera Therapeutics
Solving Big Problems with Small Molecule Degraders |
|
| |
William Forrester, Novartis
The Novartis Targeted Protein Degradation Platform |
|
| |
Gwenn Hansen †, Nurix Therapeutics
Clinical Development of Nurix’s Degrader Drugs |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–12:15 PM |
Meet the Editors |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 12:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Induced Proximity Modalities to Treat Human Disease |
|
| |
Lauren V Albrecht †, University of California Irvine
Methyl Arginine TACs |
|
| |
Steven Banik †, Stanford University
Shuttle Proteins |
|
| |
Mikko Taipale †, University of Toronto
Pervasive Mislocalization of Pathogenic Coding Variants Underlying Human Disorders: Cell |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
New Frontiers for E3 Ligases in TPD |
|
| |
Nicolas H Thomä †, EPFL Lausanne
Haven't Got a Glue: Protein Surface Variation for the Design of Molecular Glue Degraders |
|
| |
Lindsey Ingerman James †, University of North Carolina at Chapel Hill
E3 Ligase and Degrader Discovery |
|
| |
Jacob E. Corn †, ETH Zürich
C-Terminal Amides Mark Proteins for Degradation via SCF–FBXO31 |
|
| |
Christina Woo, Harvard University
Probing Cereblon Allosterically |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion: How to Start a Company |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 12:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Discovery Chemistry for Novel Induced Proximity Modalities |
|
| |
Alessio Ciulli, University of Dundee, School of Life Sciences
Trivalent TAC Chemistry |
|
| |
Nir London †, Weizmann Institute of Science
A Pharmacological Modality to Sequester Homomeric Proteins |
|
| |
Ekaterina Vinogradova †, Rockefeller University
Chemical Immunology and Proteomics for Small Molecule Degraders |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Antibody and Biologic Degraders from the Lab to the Clinic |
|
| |
Laura L. Kiessling †, Massachusetts Institute of Technology
Cell Surface Induced Proximity Engineering |
|
| |
Hui-Kuan Lin †, Duke University
Degrader Delivery through CD36 |
|
| |
John Flygare †, Eli Lilly
Delving into Novel Design and Development to Strive for Next-Generation ADCs Providing Long-Term Benefit to Patients |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:30 PM |
Glues at the AI and ML Interface |
|
| |
Bruno Emanuel Correia †, École Polytechnique Fédérale de Lausanne
PP Interface |
|
| |
Victor Guallar †, Barcelona Supercomputing Center and Nostrum Biodiscovery
Adventures in CADD |
|
| |
Daphne Koller †, insitro
AI-Driven Drug Discovery |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:30–7:15 PM |
Closing Keynote Address |
|
| |
David Baker †, University of Washington
Future of PPIs |
|
| 7:15–7:30 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:30–8:30 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
